Former Google & Facebook executive to focus on establishing product strategy, planning, and user experience for insitro’s ML-enabled platform, spanning data acquisition, processing, and analysis

insitro, a machine learning-driven drug discovery and development company, today announced that Tom Stocky has been appointed as vice president of product. Mr. Stocky has spent the majority of his career working in technology, including at Facebook, Google, and most recently in a technology-focused role at Denali Therapeutics. In his role at insitro, he will lead product strategy, planning, and user experience for insitro’s data systems and software tools.

“Our aspiration at insitro is to build a machine-learning-enabled approach to discover and advance new therapeutic interventions. Key to that vision is the construction of a platform that continually improves as we accumulate data and use them to empower novel ML methods that help de-risk and accelerate drug discovery,” said Daphne Koller, Ph.D., co-founder and CEO of insitro. “This platform is a new type of data product. To build it, we are planning to leverage the approaches that have allowed tech companies to design ML-enabled internet products that operate seamlessly and scale to hundreds of millions of users and petabytes of data. Tom was the architect and leader of some of these industry-leading products, and we are excited to have him join us to help us bring medicines to patients in need.”

"insitro is unraveling human biology, using machine learning to generate and leverage biological and chemical data that will help create safe and effective new medicines for patients," said Mr. Stocky. “They're bridging the gap between software and biology, not just from a technology perspective, but also in terms of the organization they're building. Bringing together such a diverse team — from bench scientists to data scientists, machine learning engineers to process engineers — insitro has a unique opportunity to transform drug discovery and development. I'm inspired by their mission and approach and feel lucky to join such an incredible team.”

Mr. Stocky has more than 15 years of experience building technology products. During his career, Mr. Stocky was vice president of search at Facebook, where he grew the Facebook Search service to more than 2 billion searches per day across the community's more than 3 trillion posts. He also led teams responsible for profile, entity graph, and language technology. In his prior role at Google, he helped start the developer products team and was part of the founding team for Google App Engine, which laid the foundation for Google's Cloud Platform. More recently, he served as head of learning platform at the Chan Zuckerberg Initiative, where he oversaw the engineering, product, and design teams for their education technology efforts. In his most recent role, he was a technology fellow at Denali Therapeutics, where he helped expand the use of machine learning techniques to support their discovery work and helped further develop their digital strategy for engaging with patients. Mr. Stocky serves on the board of directors of the Banner Alzheimer's Foundation and on the scientific advisory board for Denali Therapeutics. He received an MEng and B.S. in computer science & electrical engineering from MIT and an MBA from MIT Sloan.

About insitro

insitro is a data-driven drug discovery and development company using machine learning and data generation at scale to transform the way that drugs are discovered and delivered to patients. insitro’s approach focuses on the development of predictive machine learning models to be brought to bear on key bottlenecks in pharmaceutical R&D. The company has established enabling collaborations with Gilead in NASH and Bristol Myers Squibb in ALS. insitro is located in South San Francisco, CA and has been supported by top tech, biotech, and crossover investors since formation in 2018. For more information on insitro, please visit the company’s website at www.insitro.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005096/en/